课题基金 / 基金详情

RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER

RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
用于乳腺癌的重组人源化抗 185HER2 单克隆抗体
批准号：
6304677
负责人：
ADAM M BRUFSKY
金额：
$0.3万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6304677
关键词：
breast neoplasms clinical research clinical trial phase I human subject human therapy evaluation monoclonal antibody neoplasm /cancer immunotherapy recombinant proteins

项目摘要

项目成果

ADAM M BRUFSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this study is to provide an optional extension period of rhuMAb HER2 therapy to those patients whose metastatic breast cancer progressed during treatment on Protocol HO648g. It is anticipated that one patient will enter the study at the University of Pittsburgh Cancer Institute. At this time, 450 patients have entered worldwide. This is an open-label extension study of patients enrolled in protocol HO648g who developed progressive disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
海外基金